Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

NCT02323906 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
12
Enrollment
INDUSTRY
Sponsor class

Stopped Slow enrollment and business decision. No safety concerns were identified for the study drugs.

Conditions

Interventions

Sponsor

Celgene